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Current Status of Second-Line Treatment and Novel
Therapies for Small Cell Lung Cancer
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Despite high response rates to first-line standard treatment, the
great majority of patients with small cell lung cancer (SCLC) will
relapse and succumb to their disease rather quickly. In the
context of salvage therapy, symptom palliation and quality-of-
life improvements, besides survival prolongation, are primary
treatment endpoints. A variety of single-agent and multi-agent
chemotherapy regimens have been tested with limited success in
patients with recurrent SCLC. A number of combination regi-
mens have demonstrated high response rates in second-line
settings, but these can be considered only for patients with good
performance status. Treatment outcome depends on many factors,
including type of response to first-line therapy, treatment-free
interval, and performance status. Currently, topotecan represents
an effective, tolerable therapeutic option and is the only agent
approved for this indication. The management of patients with
recurrent disease remains an area of active research. This review
provides an update of clinical research on second-line chemo-
therapy of SCLC and of recent results obtained with novel
molecular targeted approaches in both first- and second-line
therapy.
Key Words: SCLC, Second-line, Target therapy.
(J Thorac Oncol. 2007;2: 764–772)
The incidence of small cell lung cancer (SCLC) is decreas-ing in the developed countries, now accounting for ap-
proximately 12% to 15% of all bronchogenic tumors, most
likely because of changes in smoking habits.1
SCLC is an aggressive tumor with a high propensity for
developing early regional and distant metastasis. It is re-
garded as highly sensitive to both chemotherapy and radia-
tion. Nevertheless, the general perception is that only modest
improvement in survival has been achieved during the last 20
years, particularly in the area of drug therapy. Worldwide, the
currently accepted standard of care for previously untreated
metastatic SCLC patients is combination chemotherapy in-
cluding cisplatin or carboplatin and etoposide.2 These regi-
mens are usually associated with a rapid objective response in
50% to 80% of patients. Nevertheless, complete responses are
seen in a minority of patients, duration of response is short,
and overall survival is still very dismal because of early
occurrence of chemotherapy-resistant disease.3
GENERAL CONSIDERATIONS ABOUT
SECOND-LINE TREATMENT OF SCLC
After the completion of first-line therapy, about 80% of
limited-disease patients and virtually all patients with exten-
sive-stage disease will develop disease relapse or progres-
sion. Prognosis of this clinical condition is extremely poor,
and most of these patients have advanced age, various co-
morbidities, poor performance status, and numerous tumor-
associated symptoms, making them unable to tolerate further
aggressive chemotherapy.4,5 Furthermore, many first-line reg-
imens are associated with cumulative toxicities, including
nephrotoxicity, neuropathy, and bone marrow suppression;
this may limit the possibility of delivering full-dose second-
line treatment safely.
Until recently, only one study, published in the late
1980s, provided any evidence that second-line treatment might
produce a survival benefit.6 In this British study, patients were
randomized among four different chemotherapy strategies, in-
cluding short (four courses) or long (eight courses) first-line
chemotherapy, both followed by either no treatment at relapse or
by second-line chemotherapy. The results of this pivotal trial
suggest that second-line chemotherapy is beneficial in patients
treated with short-term first-line therapy; this is what is currently
used in standard practice.
Nevertheless, the final confirmation of the real efficacy
of chemotherapy in second-line treatment of SCLC has been
obtained only recently, with a registration randomized study
of topotecan versus best supportive care (BSC).7 This study
has clearly shown that single-agent chemotherapy is able to
prolong survival and improve symptoms and quality of life,
compared with no active chemotherapy treatment, even in
patients with worse prognostic features.
Pretreatment variables that are able to predict clinical
outcome in recurrent disease are less well defined than those
of newly diagnosed patients.8 Retrospective studies have
found a significantly higher probability of response for those
patients who had treatment-free intervals of more than 2.6
months.9 The importance of the treatment-free interval is
further emphasized by studies investigating the value of
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rechallenge chemotherapy at relapse. Patients with a longer
treatment-free interval may still have a high probability of
achieving a second response to the same chemotherapy used
in first-line chemotherapy.10–13
Without further prospective testing, a distinction has
been made, widely accepted within the oncology community,
between patients with so-called sensitive disease: those with
a response to first-line therapy and a treatment-free interval of
90 days; and those with resistant disease: those with no
response to first-line treatment or relapse within 90 days.14
Nevertheless, it has to be stressed that this definition was
designed many years ago and was based only on small,
retrospective studies. It has not been further assessed in larger
patient series, nor has it been validated in prospective studies.
Recent studies with either single-agent chemotherapy7 or
combination chemotherapy,15 showing no difference in out-
come between sensitive and refractory patients, as classically
defined, have put the reliability of this prognostic classifica-
tion under discussion.
Despite more than 70 published studies of second-line
therapy in SCLC, no particular treatment strategy has been
clearly demonstrated to be superior to another, and to date,
only one chemotherapy agent is registered specifically for this
indication.
REINDUCTION THERAPY OR RECHALLENGE
The evidence in favor of the repetition of the same
chemotherapy used during induction (reinduction or rechal-
lenge therapy) is based on four old (1983–1988), small (6–37
patients) retrospective series (Table 1).10–13 Response rates,
obtained with various regimens in patients with a wide range
of treatment-free intervals, varied from 50% to 67%, which is
not far from what is achieved in first-line chemotherapy and
seems higher than that generally obtained with non–cross-
resistant regimens in prospective studies (about 20%).14
Whether this high response rate is attributable simply to
patient selection or to a true efficacy of this strategy in
sensitive relapse remains uncertain. In fact, in one prospec-
tive phase II study of single-agent topotecan in relapsed
SCLC, patients with disease-free intervals of more than 6
months obtained a response rate of 57%, similar to that
obtained with combination reinduction chemotherapy.16 A
final proof of the superiority of one strategy (reinduction)
over the other (non–cross-resistant chemotherapy) will re-
quire a prospective randomized study, which is currently
being planned.
CYCLOPHOSPHAMIDE, DOXORUBICIN, AND
VINCRISTINE
Because most patients are induced with platinum–
etoposide, a chemotherapy program based on cyclophospha-
mide, doxorubicin, and vincristine (CAV) to treat recurrent
disease seems a logical option. Several nonrandomized stud-
ies, including nearly 200 patients overall, have reported
objective responses in the order of 8% to 15%.17,18 The only
available randomized study compared the CAV regimen with
single-agent intravenous topotecan. Main efficacy parameters
were similar for the two types of treatment, but topotecan
seemed to provide greater symptom improvement than did
CAV. Patients receiving topotecan experienced significant
improvements in breathing difficulty, anorexia, fatigue, and
daily activity, with less neutropenia.19 Nevertheless, symp-
tom improvement was not a primary endpoint of this study,
and it was not assessed with a validated instrument. In
addition, this trial was not designed to prove noninferiority of
one treatment over the other. Therefore, whether CAV and
topotecan are truly equally effective remains to be proven
definitively.
TOPOTECAN
Most of the knowledge currently available on salvage
treatment of SCLC is attributable to the development in this
indication of a single drug, topotecan. Topotecan is a water-
soluble, semisynthetic derivative of camptothecin that has a
noncomplete, overlapping toxicity profile with other agents
used in the treatment of SCLC. Topotecan has evidenced
significant antitumor activity and symptom palliation in both
chemo-sensitive and chemo-resistant SCLC.20
Topotecan is characterized by manageable, noncumu-
lative myelosuppression and a generally favorable nonhema-
tological safety profile. This drug is currently approved for
the treatment of patients with SCLC who have failed or
relapsed after first-line chemotherapy and who are not can-
didates for reinduction.
The clinical profile of topotecan has been established in
several phase II studies16,21–23 and confirmed in randomized
phase III trials (Table 2).7,19,24 In phase II studies, topotecan
has demonstrated a response rate ranging from 11% to 31%
in chemo-sensitive patients and from 2% to 7% in chemo-
refractory ones, with median survival rates of 25 to 36 weeks
and 16 to 21 weeks, respectively.16,21–23
The approval of topotecan in the United States and,
subsequently, in Europe was based primarily on data from
three phase III trials.7,19,24 One trial, as previously reported,
compared intravenous topotecan with CAV.19 A second trial
comparing oral versus intravenous topotecan found both
formulations to be similarly well tolerated and effective in
this patient population (median overall survival, 33.0 weeks
versus 35.0 weeks).24 The better hematological toxicity pro-
file suggests that oral topotecan may be a preferable thera-
peutic modality, especially for patients with poor perfor-
mance status, offering greater ease of use for treating
TABLE 1. Studies of Reinduction Therapy (or Rechallenge)
in Small Cell Lung Cancer
Study Chemotherapy
No. of
Patients
Response
Rate (%)
Batist et al.10 Various 6 66
Postmus et al.11 CDE 37 62
Giaccone et al.12 CDE/CAV/PE 13 50
Vincent et al.13 Various 15 67
CDE, cyclophosphamide, doxorubicin, and etoposide; CAV, cyclophosphamide,
doxorubicin, and vincristine; PE, cisplatin and etoposide.
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physicians and better convenience to patients.25,26 In the third
trial, addition of oral topotecan to BSC was associated with a
significant increase in median overall survival compared with
BSC alone (25.9 weeks versus 13.9 weeks; p  0.01).7 In
addition, patients on topotecan had slower quality-of-life
deterioration and greater symptom control. Interestingly, ben-
efits in survival and quality of life were evident even in the
worse patient subgroups, such as those with poor perfor-
mance status and refractory disease.
Although the recommended starting dose of topotecan
is 1.5 mg/m2 on days 1 through 5 of a 21-day cycle, advanced
age, extensive pretreatment, prior platinum therapy, prior
radiotherapy, and renal impairment are potential risk factors
for increased myelosuppression during topotecan therapy.20
Lower-dose topotecan regimens have been evaluated in at-
tempts to minimize hematological toxicity and to maintain
the efficacy of topotecan in patients at higher risk. Results
from these studies suggest that topotecan at doses of 1.0 to
1.25 mg/m2 on a 5-day schedule, or 1.25 to 1.5 mg/m2 on a
3-day schedule or weekly (4.0 mg/m2/week) schedules may be
more appropriate for patients with associated risk factors.20,27
Reversible, nonoverlapping, nonhematological toxici-
ties and in vitro antitumor synergy with platinum agents,
taxanes, and topoisomerase II inhibitors may make topotecan
an ideal candidate for use in combination with other chemo-
therapy agents. Topotecan was tested with cisplatin, either in
first- or second-line treatment, and with other drugs. All of
these combinations are feasible and active.20 Further investi-
gations are needed to demonstrate an improved efficacy of
topotecan-based combination regimens compared with sin-
gle-agent treatment in the second-line setting.
OTHER CHEMOTHERAPY AGENTS
Several other agents, including paclitaxel, docetaxel,
vinorelbine, gemcitabine, and irinotecan have been investi-
gated as second-line treatments of SCLC (Table 2).5,14,28
Paclitaxel has been found to have a response rate of
20% to 29% in patients with refractory SCLC.29,30 It also has
been studied within combination regimens (with carbopla-
tin,31,32 doxorubicin,33,34 gemcitabine,35,36 or cisplatin and
ifosfamide37) in phase II trials with relatively small numbers
of patients with both sensitive and refractory disease. The
data from these studies demonstrate that the different tested
regimens were active (response rates from 25% to 73.5%)
and well tolerated as salvage treatments in SCLC patients.
The most impressive result, which would require confirma-
tion in a larger patient population, is probably the 73%
response rate achieved with the combination of paclitaxel and
carboplatin in refractory SCLC.31
Docetaxel has been evaluated as monochemotherapy in
this setting in a phase II trial, showing an activity of 25%.38
In addition, gemcitabine and vinorelbine also have shown
single-agent activity in recurrent SCLC patients. Gemcitabine
has been shown to have an overall response rate of 12% to
13% as a second-line treatment in two phase II studies,39,40
but a third trial has shown no response in either sensitive or
resistant patients.41 The gemcitabine–irinotecan combination
has been studied extensively. Five phase II trials have had
conflicting results, reporting response rates ranging from 10%
to 50% and having different conclusions, especially for re-
fractory patients.42–46 Gemcitabine also has been tested in
association with docetaxel47 and vinorelbine,48,49 with disap-
pointing results, particularly in refractory disease. Activity of
vinorelbine as a single agent has been reported to be 16% and
12.5% in two studies that had 25 and 24 SCLC relapsed
patients, respectively.50,51
Response rates for irinotecan were similar to those of
topotecan, both in patients with sensitive disease (30%) and
in patients with refractory disease (less than 10%), with a
median survival ranging from 5 to 7 months.52 CPT-11 also
has demonstrated interesting activity when combined with
etoposide, cisplatin, carboplatin, and ifosfamide.52
In summary, it can be concluded that most agents tested
in the second-line treatment of SCLC have shown some
degree of activity. Nevertheless, the uneven distribution of
sensitive versus refractory patients in the various studies, and
the lack of comparative trials, prevent any conclusions about
the superiority of one agent over the other. More recently,
new chemotherapy agents such as amrubicin and pemetrexed
have been tested in the second-line treatment of SCLC.
Amrubicin is a completely synthetic 9-aminoanthracy-
cline that functions as a topoisomerase II inhibitor. Two
phase II studies with amrubicin in a Japanese population with
previously treated SCLC have shown impressive results.53,54
The first study administered amrubicin at doses of 40 mg/m2
per day on days 1 through 3, with cycles repeated every 21
days for a total of four cycles. The primary endpoint was an
objective response. To be eligible, patients must have re-
ceived one or two previous chemotherapeutic regimens, with
at least one regimen containing a platinum agent. Sixty
patients were enrolled: 44 with chemo-sensitive disease and
16 with refractory disease. Interestingly, the response rate
was around 50% in both sensitive and refractory patients. The
overall median survival time was 11.2 months, with a 1-year
TABLE 2. Single-Agent Chemotherapy in Second-Line
Treatment of Small Cell Lung Cancer
Drug
Phase of
Trial
First-Line
Chemotherapy
Sensitivity
Total
No. of
Patients
Response
Rate* (%)
Topotecan 7,16,19,21–24 II–III S 654 7–38
R 217 2–7
Paclitaxel29,30 II R 117 20–29
Docetaxel38 II S/R 34 25
Gemcitabine39–41 II S 41 0–12
R 73 0–13
Vinorelbine50,51 II S/R 50 12.5–16
Irinotecan52 II S/R 16 47
Amrubicin53,54 II S 68 50–52
R 26 50–60
Pemetrexed55,56 II S 42 4–5
R 35 3–4
S, sensitive disease; R, refractory disease; S/R, data not divided according to
first-line chemotherapy sensitivity. *Range of reported response rate.
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survival rate of 44.1%.53 The second, smaller study by Kato
and colleagues enrolled 35 patients who had received one or
two previous chemotherapy regimens. These patients were
given amrubicin at doses of 45 mg/m2 per day for 3 days.
Thirty-four patients were evaluable, 24 of whom had sensi-
tive relapses and 10 of whom had resistant relapses. Response
to treatment was again similar in the two prognostic sub-
groups: 50% and 60% in the sensitive- and refractory-relapse
patients, respectively. The overall survival rate was 9.2
months, with a 1-year survival rate of 26.5%.54 Although the
efficacy of amrubicin is certainly impressive, particularly in
the group of refractory patients, toxicity is also significant.
Grade 3/4 neutropenia rate was 83% in the first study (febrile
neutropenia occurred in 5%) and 97% in the second (febrile
neutropenia occurred in 35%). Amrubicin is currently being
developed in both first- and second-line SCLC treatment; in
particular, a randomized phase III trial of amrubicin versus
topotecan is planned in sensitive and refractory patients.
Pemetrexed, a multitargeted antifolate recently ap-
proved for use in mesothelioma and in second-line treatment
of non-small cell lung cancer, does not seem to have much
activity in SCLC. Data from two phase II studies of 43
patients (20 with chemo-sensitive disease and 23 with chemo-
resistant disease) and 34 patients (22 with chemo-sensitive
disease and 12 with chemo-resistant disease) who had re-
ceived prior chemotherapy regimens were presented.55,56 In
the first trial, 500 mg/m2 of pemetrexed was administered
intravenously every 3 weeks, with vitamin supplementation
and dexamethasone prophylaxis. Only two patients achieved
partial responses, and two others demonstrated stable disease.
The predetermined criteria for increasing the sample size to
96 patients were, therefore, not met.55 In the second trial, with
pemetrexed in doses of 900 mg/m2 for a maximum of four
courses, the response rate was too low (4.5% and 2.9% in
sensitive and refractory patients, respectively) to recommend
single-agent pemetrexed for second-line chemotherapy in the
treatment of SCLC.56 Pemetrexed is not being developed
further for second-line treatment, but a large noninferiority
trial has been launched recently for first-line treatment.
TARGETED THERAPIES
Given the limited improvements obtained with last-
generation chemotherapy agents in the treatment of SCLC,
high priority is currently given to research of novel molecular
target agents. Nevertheless, to date, no targeted therapies
have been found to alter the clinical history of SCLC.57 In this
section, the most promising agents and pivotal trials in the
first- and in second-line treatment of SCLC patients are
reviewed (Table 3).
SIGNAL-TRANSDUCTION INHIBITORS
Protein farnesylation is the covalent addition of a far-
nesyl (15-carbon) group to the cysteine residue located in
several G-proteins involved in cell signaling, such as the Ras
protein, which is crucial for membrane interaction. R115777
(Zarnestra) is an oral farnesyl transferase inhibitor that has
been tested in a multicenter phase II trial in sensitive relapse
SCLC patients.58 This agent has shown no significant activity
as a single agent in second-line treatment, with remarkable
renal toxicity.
c-Kit targeting was believed to be a promising biolog-
ical therapeutic strategy, given the frequent overexpression
(around 70% of cases) of this stem cell factor–binding
tyrosine kinase receptor in SCLC. Imatinib mesylate, the
prototype of c-Kit tyrosine kinase inhibitors, has been shown
to produce in vitro growth inhibition of SCLC cell lines
expressing c-Kit.59 In addition, this targeted therapy has been
found active in patients with other c-Kit–positive tumors,
such as GIST. Contrary to expectations, three phase II trials
TABLE 3. Targeted Therapies Investigated in Small Cell Lung Cancer
Drug Mechanism of Action Stage of Development Outcome
Farnesyl transferase inhibitors
R115777 (Zarnestra) FT inhibitor Phase II Negative
Imatinib mesylate (Glivec) Small-molecule TKI ofc-Kit, bcr-abl, PDGFR Phase II Negative
Gefitinib (Iressa) Small-molecule TKI of EGFR Phase II Negative
CCI-779 (Temsirolimus) mTOR inhibitor Phase II Ongoing
Thalidomide Immunomodulatory Antiangiogenic Phase III Survival benefit
ZD6474 (Zactima) Small-molecule TKI ofVEGFR and EGFR Phase II Ongoing
Bevacizumab (Avastin) Monoclonal antibody against VEGF Phase II Ongoing
Matrix metalloproteinase inhibitors
Marimastat MMP inhibitor Phase III Negative
BAY 12-9566 (Tanomastat) MMP inhibitor Phase III Negative
G3139 (Oblimersen) Bcl-2 antisenseoligonucleotide Phase II Ongoing
PS-341 (Bortezomib) Proteasome inhibitor Phase II Ongoing
BEC2/BCG Monoclonal antibody Phase III Negative
p53 vaccine Dendritic cell vaccine Phase II Negative
BB-10901 Immunoconjugate of anti-CD56 antibody and DM1 Phase II Ongoing
FT, farnesyl transferase; TKI, tyrosine kinase inhibitor; PDGFR, platelet-derived growth factor receptor; EGFR, epidermal growth factor receptor; mTOR, mammalian target of
rapamycin; VEGFR, vascular endothelial growth factor receptor; VEGF, vascular endothelial growth factor; MMP, matrix metalloproteinase; BCG, bacille Calmette–Gue´rin.
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have not shown any activity of imatinib in SCLC pa-
tients.60–62 The most likely explanation for these findings lies
in the subsequent observation that SCLC cells do not bear
constitutive mutations in the target coding genes, as GIST
and CML cells do.63
Unlike non-small cell lung cancer, SCLC tumors and
cell lines do not express at all, or express in very small
amounts, epidermal growth factor receptor (EGFR); conse-
quently, the use of EGFR inhibitors (gefitinib, erlotinib) in
SCLC has not been shown to be worthwhile.64 Nevertheless,
gefitinib has been shown to inhibit EGFR signaling in SCLC
cell lines that express the receptor even at a low level,
suggesting the occasional presence of functional EGFR in
SCLC.65 A phase II trial of gefitinib in patients with relapsed
neuroendocrine tumors, in which 18 of 19 patients had SCLC,
failed to demonstrate any responses.66 Nevertheless, two
independent groups have reported two cases of response to
gefitinib in never-smoker SCLC patients with EGFR muta-
tion, suggesting that EGFR tyrosine kinase inhibitors may be
a treatment option for a small subset of SCLC tumors that
express functional EGFR.67,68
The mammalian target of rapamycin is a downstream
mediator in the phosphoinositide 3-kinase/AKT signaling
pathway, which plays a central role in regulating cellular
growth and proliferation. There are several mammalian target
of rapamycin inhibitors that have entered clinical trials,
including CCI-779 (temsirolimus), which has demonstrated
antitumor activity in a number of cancer models. Preliminary
results of a randomized phase II trial of temsirolimus after
induction chemotherapy for extended SCLC have been re-
ported.69 Eighty-seven patients have been randomized to two
dose levels of temsirolimus (25 or 250 mg) weekly until
disease progression. The median progression-free survival
and the median overall survival for all patients were 2.2 and
7.8 months, respectively, with a slight increase for the higher-
dose arm (progression-free survival, 1.8 months versus 2.5
months; overall survival, 6.5 months versus 9 months).
ANGIOGENESIS INHIBITORS
Neoangiogenesis (evaluated through microvessel
count) and overexpression of vascular endothelial growth
factor are abundant in SCLC and are associated with poor
prognosis.70 For this reason, SCLC is believed to be an ideal
model for testing antiangiogenic drugs; in fact, most of these
are being evaluated in clinical trials.
Thalidomide is known to possess both immunomodu-
latory and antiangiogenic properties. At a dosage of 100 to
500 mg/day, the main toxicities of thalidomide are fatigue,
nausea, and vomiting. In a phase II trial, thalidomide (100 mg
per day, for up to 2 years) was administered concomitantly to
carboplatin plus etoposide in 25 SCLC patients, with evi-
dence of objective responses in 68% of cases and a median
overall survival of 10.2 months.71 As a maintenance treat-
ment, thalidomide was studied in other two studies: one phase
II and one phase III, respectively.72,73 In the first study, 30
patients with metastatic SCLC not progressing after first-line
chemotherapy received 200 mg of thalidomide per day as
maintenance therapy, starting 3 to 6 weeks after completion
of chemotherapy.72 Toxicity was minimal; median survival
from the time of initiation of induction chemotherapy was
12.8 months, with a median duration on thalidomide of 79
days. In the second study, thalidomide maintenance treatment
was evaluated in a phase III trial by the Federation National
de Centres de Lutte contra le Cancer Group in France.73
Ninety-two extensive-SCLC patients with performance status
up to 2, age 70 years, were randomized to placebo or
thalidomide (400 mg per day planned; reduced to 200 mg in
half of the patients) starting after two cycles of induction
treatment with cisplatin, cyclophosphamide, doxorubicin, and
etoposide. Overall survival was 8.7 and 11.7 months for
placebo and thalidomide, respectively (p  0.03). A large,
randomized UK trial has been recently closed; this should
confirm or deny the role of thalidomide in SCLC.
Other antiangiogenic agents such as ZD6474 (oral in-
hibitor of tyrosine kinase activity of either EGFR and vascu-
lar endothelial growth factor receptor) and bevacizumab, a
monoclonal antibody directed against vascular endothelial
growth factor, are under phase II evaluation in SCLC.57 In
particular, bevacizumab was tested as a maintenance therapy
after carboplatin–irinotecan and radiotherapy in 57 patients
with limited SCLC.74 Safety, response rate (80%), and sur-
vival (15 months) of chemoradiotherapy and then bevaci-
zumab compare favorably with standard treatment for limited
SCLC. Randomized studies to assess the role of bevacizumab
in improving overall survival in SCLC are being planned.
Matrix metalloproteinases (MMPs) are a family of
enzymes responsible for remodeling the extracellular matrix,
which is important in tumor invasion, angiogenesis, and
metastatic processes. In SCLC, increased expression of
MMPs and their tissue inhibitors has been reported and has
provided the rationale for clinical trials of synthetic MMP
inhibitors.75 Research in this area has been stopped after the
results of a phase III randomized trial of marimastat, a
synthetic MMP inhibitor, versus placebo after induction che-
motherapy for SCLC became available.76 This large trial (532
patients) demonstrated that the treatment with marimastat did
not result in an improved survival (median time to progres-
sion of 4.3 months versus 4.4 months and median overall
survival of 9.3 months versus 9.7 months for marimastat and
placebo, respectively) and had a negative impact on quality of
life. A similar outcome was obtained with another MMP
inhibitor, BAY 12-9566 (tanomastat).57
ANTI-BCL-2 AND APOPTOSIS-INDUCTION
THERAPIES
The majority of SCLC cell lines express the antiapop-
totic protein bcl-2; this may represent one mechanism by
which this tumor rapidly becomes resistant to chemotherapy.
Suppression of bcl-2 levels through the use of G3139
(oblimersen), an antisense oligonucleotide complementary to
the mRNA encoding bcl-2, might increase the antitumor
efficacy of cytotoxic therapy. After being tested in two phase
I trials in combination with paclitaxel (second line)77 and
with carboplatin and etoposide (first line),78 respectively,
oblimersen has been evaluated in a randomized phase II trial
combined with carboplatin and etoposide versus chemother-
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apy alone in the first-line treatment of extensive-stage SCLC.
Initial results demonstrate objective responses in 67% in the
oblimersen arm, with a trend for a higher incidence of grade
4 toxicity. Final analyses of efficacy and toxicity data are
awaited.79
Proteasome inhibitors target the 26S proteasome, a
major component of the ubiquitin proteasome pathway re-
sponsible for intracellular protein degradation. Cancer over-
expression of 26S proteasome results in accelerated degrada-
tion of regulatory proteins, leading to uncontrolled cell
division. Inhibition of 26S proteasome leads to accumulation
of these regulatory proteins, disruption of the cell cycle, and
inhibition of cell growth. Among these mechanisms, break-
down inhibition of the inhibitory protein I-B, which inhibits
the nuclear factor-B pathway,80 seems to be the most crucial
one. Under stress conditions, including exposure to chemo-
therapy or ionizing radiation, I-B is phosphorylated,
prompting ubiquitination and degradation by the proteasome.
This allows release of nuclear factor-B, which activates
transcription of a number of genes involved in a variety of
cellular functions, such as growth factors, cytokines, anti-
apoptotic factors, and cell-adhesion molecules. Bortezomib
(PS-341) has been the first proteasome inhibitor to be eval-
uated in clinical trials. In SCLC cell lines, bortezomib has
been shown to reduce bcl-2 levels via inhibition of nuclear
factor-B activity, thereby inducing apoptosis.81 Neverthe-
less, in a phase II trial of single-agent bortezomib in plati-
num-pretreated extensive-stage SCLC patients, only one par-
tial response was reported out of 57 evaluable patients.82 It
has been suggested that a greater effect may be achieved if
proteasome inhibition is combined with a proapoptotic trigger
such as chemotherapy.
IMMUNOTHERAPY
Numerous tumor cell-surface antigens have been iden-
tified as potential target for immunotherapy in SCLC. Bec2
(mitumomab) is an anti-idiotypic mouse IgG2b monoclonal
antibody that mimics the ganglioside GD3 expressed on the
surface of most SCLC tumors, combined with bacillus
Calmette–Gue´rin as an immune adjuvant. The hypothesis is
that active immunization could alter the natural history of the
disease by eradicating micrometastases, thereby improving
survival in patients with SCLC who have completed induc-
tion therapy. This approach has shown promising results in a
pilot study83 and has been tested subsequently in a phase III
European Organization for Research and Treatment of Can-
cer study (SILVA trial), in which 515 patients with limited
SCLC were randomized to receive Bec2 or no treatment as
maintenance after standard treatment.84 In this trial, vaccina-
tion with Bec2/bacillus Calmette–Gue´rin demonstrated no an
impact on any outcome measure in patients with limited-
disease SCLC after standard chemoradiation.
The tumor-suppressor gene p53 plays an essential role
as a regulator of cell growth and differentiation, and it is
mutated in 90% of SCLCs.85 Preclinical studies have shown
that the induction of an anti-p53 cytotoxic T-lymphocyte
response selectively kills tumor cells and spares normal
cells.86 In a recently reported trial, 29 patients with extensive
SCLC who had received induction chemotherapy were
treated with a vaccine consisting of dendritic cells transduced
with the full-length wild-type p53 gene delivered via an
adenoviral vector.87 In this study, p53-specific T-cell re-
sponses were observed in 57% of patients. Nevertheless, only
one objective clinical response was observed. Of note, the
response rate to subsequent chemotherapy was 61.9% (75%
of patients who developed a p53-specific response versus
only 30% of p53 nonresponders; p 0.08)—higher than that
usually seen in the second-line setting. The precise mecha-
nism behind this apparent effect is unclear and needs further
elucidation.
BB-10901 is an immunoconjugate of the cytotoxic
maytansinoid drug DM1, with a humanized version of the
murine monoclonal antibody N901. It binds with strong
affinity to the CD56 antibody, which is expressed in a variety
of tumor types, including SCLC. On binding to CD56, the
drug is internalized and DM-1 is released, inhibiting tubulin
polymerization and, therefore, causing cell death. In preclin-
ical studies, BB-10901 has shown marked efficacy against
SCLC xenograft models, and in an ongoing phase II clinical
trial it has shown two partial responses and another minor
response in 10 patients with relapsed SCLC.88
CONCLUSIONS
Relapsed SCLC still represents a challenge, both for
treating physicians and for oncology researchers. Although
significant improvements in the quantity and quality of sur-
vival can be achieved with currently available treatments, the
overall results remain largely unsatisfactory, and there is an
obvious need for further advances. The interest among clin-
ical oncologists and the pharmaceutical industry in such a
tremendous disease seems to have diminished more so than
has the number of SCLC cases. Setting up clinical trials
assessing novel therapeutic strategies in SCLC is difficult
compared with other tumor types, but doing so is absolutely
necessary.
Topotecan is an important addition to our armamentar-
ium for the treatment of relapsed SCLC, but it remains the
only approved therapy after the failure of first-line chemo-
therapy. Although topotecan has demonstrated consistent,
reproducible antitumor activity, which translates into survival
extension and quality-of-life improvement, hematological
toxicity and the 5-day intravenous schedule remain as prob-
lems. The availability of a topotecan oral formulation will
partially overcome these limitations. In addition, the role of
topotecan in combination regimens and in comparison with
rechallenge therapy or other non–cross-resistant regimens
has yet to be clarified. At any rate, the development of more
effective, tolerable treatments remains an unmet medical
need. Among the new chemotherapy agents under develop-
ment, amrubicin deserves attention, given the promising ac-
tivity demonstrated in preliminary studies.
Our progressive understanding of most crucial molec-
ular events associated with SCLC progression increases the
potential for the development of novel, more effective tar-
geted agents. Maximizing the potential of these drugs and
defining their role alongside traditional chemotherapy agents
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represents a current research priority. Nevertheless,, none of
the biological agents tested have met the expectations so far.
Recently, there has been some glimmer of hope that the
antiangiogenic approach, which has allowed a significant step
forward in other malignancies, might lead to improved out-
comes in lung cancer patients with small cell histology.
Recent data from newer agents belonging to this class allow
some cautious optimism for future advances in the treatment
of this complex and challenging disease.
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